×

VivoCAR™ Anti-PSMA (chv75-2a11) h(CD28-41BB-CD3z) CAR saRNA (XS-0326-XU98)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

VivoCAR™ Anti-PSMA (chv75-2a11) h(CD28-41BB-CD3z) CAR saRNA leverages high-efficiency saRNA to deliver the chv75-2a11 clone. In the landscape of in vivo CAR-T for prostate cancer, this clone is highly valued for its binding to the extracellular domain of PSMA. The biological magnification effect of saRNA ensures that a minimal systemic dose leads to robust CAR expression, enabling T cells to reprogram in situ and effectively target PSMA-positive metastatic lesions even in the presence of soluble PSMA variants.

  Add to Cart

CAR Information

  • Target
  • PSMA
  • Target Species
  • Human
  • Antibody Clone
  • chv75-2a11
  • scFv Host Species
  • Human
  • Receptor Construction
  • CD28-41BB-CD3z
  • Generation
  • Third
  • Description of Signaling Cassetes
  • The third-generation CD28-41BB-CD3ζ architecture employs a sequential costimulatory strategy, where the CD28 module drives rapid initial activation and metabolic reprogramming, while the 4-1BB component sustains long-term cellular viability and mitigates exhaustion. This tandem design, anchored by the CD3ζ signaling chain, synergistically amplifies downstream signal transduction, resulting in a balanced T-cell phenotype with robust effector capacity and prolonged durability. The integrated signaling cascade thus optimizes both kinetic expansion and persistence, enhancing antitumor efficacy.

CAR saRNA Properties

  • Structure
  • Linear
  • Cap
  • Cap 1
  • PolyA
  • Segmented PolyA
  • Product Type
  • CAR IVT saRNA
  • Concentration
  • Lot specific
  • Buffer
  • 1 mM Sodium Citrate, pH 6.4 (or specialized RNA storage buffer, RNase-free).
  • Storage
  • Aliquot and store at -80°C. Avoid freeze/thaw cycles.
  • Handling
  • Thaw and work with RNA on ice. Upon first use, pulse spin before opening and aliquot into single use portions. DO NOT vortex. Use only certified RNase-free reagents and consumables with proper RNase-free technique. Use of barrier tips is recommended. Avoid freeze/thaw cycles. DO NOT mix with media containing serum unless first complexed with a stabilizing transfection reagent.

saRNA Quality Control

  • IVT Vector Sequencing
  • Pass
  • IVT Vector Enzyme Digestion
  • Pass
  • Purity OD260/280
  • Pass
  • RNA Length and Integrity Assessment (Determined by Denaturing Agarose Gel Electrophoresis)
  • Pass
  • RNA Sequence Assessment
  • Pass
  • Endotoxin (<10 EU/mg)
  • Pass
  • In Vitro Transfection and Expression (Optional)
  • Pass

Target Information

  • Full Name
  • Prostate-Specific Membrane Antigen
  • Alternative Names
  • PSM; FGCP; FOLH; GCP2; FOLH1; mGCP; GCPII; NAALAD1
  • Introduction
  • PSMA is a type II transmembrane protein that is significantly upregulated in prostate cancer cells and the neovasculature of many solid tumors, making it a premier target for cell-based and radioligand therapies.
  • Targeting Diseases
  • Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Renal Cell Carcinoma

Case Studies

Customer Reviews and Q&As

There are currently no customer reviews or questions for VivoCAR™ Anti-PSMA (chv75-2a11) h(CD28-41BB-CD3z) CAR saRNA (XS-0326-XU98). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

Key Updates
Newsletter. (Creative Biolabs Authorized) NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution. (Creative Biolabs Authorized) NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
Novel Solution. (Creative Biolabs Authorized) NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
New Technology. (Creative Biolabs Authorized) NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.